Assessing the Clinical Utility of Proviral DNA-based Antiretroviral Drug Resistance Testing in Individuals Living with Human Immunodeficiency Virus Type 1

评估基于 Proviral DNA 的抗逆转录病毒耐药性检测在 1 型人类免疫缺陷病毒感染者中的临床效用

• 批准号: 449333
• 负责人: Sudderuddin K Hanwei
• 金额: $ 1.27万
• 依托单位: University of British Columbia
• 依托单位国家: 加拿大
• 项目类别: Studentship Programs
• 财政年份: 2020
• 资助国家: 加拿大
• 起止时间: 2020-12-01 至 2021-12-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=449333&lang=en
• 关键词: Antiretroviral Therapy; Archived Proviral Hiv Dna Genotype; Bioinformatics; Biostatistics; Hiv Antiretroviral Treatment Guidelines; Hiv Drug Resistance; Hiv-1; Hiv-1 Proviral Dna; Hiv-1 Proviral Dna Resistance Testing; Next-Generation Sequencing

Globally, Human Immunodeficiency Virus (HIV) infects 38 million people, including over 68,000 Canadians. These individuals must take antiretroviral therapy (ART) that blocks HIV replication and thereby significantly improves quality and duration of life.

在全球范围内，人类免疫缺陷病毒（艾滋病毒）感染了3 800万人，其中包括68 000多名加拿大人。这些人必须接受抗逆转录病毒治疗（ART），阻止艾滋病毒复制，从而显着提高生活质量和寿命。